Real-world Daptomycin Use in Chinese ICUs

S

Sichuan University

Status

Completed

Conditions

Daptomycin
Intensive Care Unit
Real-world Study

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT03588637
HX 00147

Details and patient eligibility

About

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Enrollment

200 patients

Sex

All

Ages

1 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient who received at least one dose of daptomycin

Exclusion criteria

No

Trial design

200 participants in 1 patient group

Study population
Description:
Patient who receive at least one dose of daptomycin
Treatment:
Other: No intervention

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems